The S&P 500 has had a volatile start to 2025 but has still managed to gain 3.8% year to date as of market close on Jan. 24.

It was about a year ago that shares of Iovance Biotherapeutics ( IOVA -1.94%) began to take off. The stock soared on news of approval from the Food and Drug Administration for Amtagvi (lifileucel) as ...

Buybacks continue to progress, and GM met its goal of fewer than 1 billion outstanding shares at the end of 2024. Plus, the company is improving its balance sheet, paying off $750 million in debt ...

Dan Ives leads technology research at Wedbush Securities and has long been an Nvidia bull. Despite the news out of DeepSeek, Ives remains incredibly optimistic about Nvidia's future and just called ...

With growth coming in hot, Axon Enterprise's shareholders enjoyed a great year. In 2024, Axon stock jumped 130%, skyrocketing ...

Looking ahead to fiscal 2025, Tractor Supply is targeting net sales growth in the mid-single digits, with an EPS range ...

Microsoft posted strong Q2 2025 earnings, beating expectations with robust cloud and AI growth, though it faces challenges in ...

Like all companies, American Express' fortunes wax and wane over time. But if you think in decades and not days, it is a very ...

The latest U.S. Federal Reserve meeting saw interest rates remain on hold as it seeks to make more progress on lowering ...

Palantir would need to grow into a $6.7 trillion market cap to turn a $25,000 investment into $1 million. This would be its ...

The transformative power of artificial intelligence (AI) is undeniable. A recent McKinsey & Company research report estimates ...

In a nutshell, Innovative Industrial Properties' stock is way down because the REIT's largest tenant, PharmaCann, has fallen ...